Endovia Health Sciences raises $81.8K in stock sale

C/M Capital Master Fund, LP's resales of the shares were registered on a Form S-1 effective August 24, 2026.

Rhea-AI Filing Summary

Endovia Health Sciences, Inc. (EDVA) sold and issued 526,582 shares of common stock to C/M Capital Master Fund, LP on September 30, 2026, for total gross proceeds of $81,830.84 under a Securities Purchase Agreement dated September 19, 2025. To the extent the sales are deemed unregistered, Endovia stated they were made under the exemptions provided by Section 4(a)(2) and Rule 506(b); the purchaser’s resales were registered on a Form S-1 effective August 24, 2026.

Filing Explained

The September 30 issuance of 526,582 shares increases Endovia’s share count and reduces existing holders’ percentage ownership absent offsetting changes.

8-K Event Classification

Item 3.02 — Unregistered Sales of Equity Securities

1 item

Item 3.02 Unregistered Sales of Equity Securities Securities

The company sold equity securities in a private placement or other unregistered transaction.

Key Figures

Common shares issued: 526,582 shares Gross proceeds: $81,830.84 Securities Purchase Agreement date: September 19, 2025 +1 more

4 metrics

Common shares issued 526,582 shares September 30, 2026

Gross proceeds $81,830.84 From the September 30, 2026 share issuance

Securities Purchase Agreement date September 19, 2025 Agreement with C/M Capital Master Fund, LP

Form S-1 effective date August 24, 2026 Registration of the purchaser’s resales

Key Terms

Securities Purchase Agreement, gross proceeds, Section 4(a)(2), Rule 506(b)

4 terms

Securities Purchase Agreement financial

"Securities Purchase Agreement dated September 19, 2025"

A securities purchase agreement is a written contract between a buyer and a seller outlining the terms for buying or selling financial assets such as stocks or bonds. It specifies details like the price, quantity, and conditions of the transaction, similar to a shopping list with agreed-upon terms. For investors, it provides clarity and legal protection when transferring ownership of these financial instruments.

gross proceeds financial

"for total gross proceeds of $81,830.84"

The total amount of cash a company receives from a financing event or sale before any fees, expenses, taxes or deductions are taken out. Investors watch gross proceeds because it shows the raw scale of new capital being raised—think of it as the paycheck amount before withholdings—which helps assess how much funding is available for operations, growth, debt payoff or how much shareholder dilution might occur once costs are removed.

Section 4(a)(2) regulatory

"exemption from registration provided under Section 4(a)(2)"

Section 4(a)(2) is a part of U.S. securities laws that allows companies to sell their stock directly to certain investors without registering the sale with regulators. This process is often used for private placements, making it easier and faster for companies to raise money from knowledgeable or institutional investors. It matters to investors because it provides an alternative way to buy shares, often with fewer disclosures and lower costs.

Rule 506(b) regulatory

"Rule 506(b) promulgated thereunder"

Rule 506(b) is a U.S. securities exemption that lets companies sell shares or debt privately without full public registration, provided sales are primarily to accredited investors, up to 35 non‑accredited but financially knowledgeable buyers, and there is no public advertising or solicitation. It matters to investors because offerings under 506(b) usually include less public disclosure than registered securities—like buying from a private seller rather than a retail store—so buyers must do more of their own fact‑checking and rely on their financial sophistication.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many EDVA shares did Endovia issue, and what were the gross proceeds?

Endovia sold and issued 526,582 shares of common stock to C/M Capital Master Fund, LP on September 30, 2026, for total gross proceeds of $81,830.84 under the Securities Purchase Agreement dated September 19, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/06/2026 - 04:10 PM Accepted by SEC EDGAR 10/06/2026 - 04:10 PM Learn about SEC filing dates

false 0001553788 0001553788 2026-09-30 2026-09-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 30, 2026

ENDOVIA HEALTH SCIENCES, INC.

(Exact name of registrant as specified in its charter)

Nevada		001-40471		34-1720075
(State or other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

1112 N. Flagler Drive Fort Lauderdale, Florida		33304
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (954) 648-7238

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value		EDVA		NYSE American LLC

Item 3.02 Unregistered Sales of Equity Securities.

On September 30, 2026, Endovia Health Sciences, Inc. (the “Company”) sold and issued a total of 526,582 shares of common stock pursuant to that certain Securities Purchase Agreement dated September 19, 2025 with C/M Capital Master Fund, LP as purchaser (the “ELOC Agreement”) for total gross proceeds of $81,830.84. The ELOC Agreement was previously disclosed in the Company’s Current Report on Form 8-K filed on September 25, 2025. To the extent such sales are deemed to be unregistered, the sales were made pursuant to the exemption from registration provided under Section 4(a)(2) of the Securities Act of 1933 and Rule 506(b) promulgated thereunder. The purchaser’s resales of the shares were registered on the Company’s registration statement on Form S-1 (File No. 333-298112), effective August 24, 2026.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ENDOVIA HEALTH SCIENCES, INC.
Date: October 6, 2026	By:	/s/ Brady Cobb
	Name:	Brady Cobb
	Title:	Interim Chief Executive Officer

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL SCHEMA FILE 2.9 KB
• EX-101 XBRL LABEL FILE 33.4 KB
• EX-101 XBRL PRESENTATION FILE 21.8 KB